Sunday 05 February 2023
Ibn Sina Pharma, which operates in the field of drug distribution, has signed an agreement with Boehringer Ingelheim, the global drug production company, to distribute its treatments in the fields of cardiovascular and respiratory treatment in Egypt, according to a statement sent by Ibn Sina to the Stock Exchange today.
Marianne Abu Al-Khair, General Manager and Head of the Human Medicines Sector at Boehringer Ingelheim for the Levant and Northeast Africa, said that this partnership confirms the company’s commitment to providing sustainable treatments for patients, and that the company is confident that through its cooperation with Ibn Sina Pharma, it will provide its best. From collective expertise and market knowledge to provide high quality healthcare.
Mohsen Mahgoub, CEO of Ibn Sina Pharma, said that his company hopes, through this agreement, to provide citizens in Egypt with biopharmaceuticals invented by Boehringer Ingelheim that cover important areas of diseases such as type 2 diabetes, high blood pressure, and respiratory diseases, in addition to to stroke.
Ibn Sina Pharma was established in 2001 and operates in the field of drug distribution and occupies the second position in terms of market share and specializes in distributing products of more than 350 companies, according to the statement.
Leave a Reply